Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Fate Therapeutics will work with Johnson and Johnson on iPSC-derived CAR cell therapies in a deal worth up to 3.1 billion dollars. Janssen Biotech will pay…
Johnson and Johnson's pharmaceutical unit Janssen Biotech struck a worldwide collaboration deal with Fate Therapeutics worth as much as 3.1 billion dollars on…
Fate Therapeutics and Janssen have ended their worldwide collaboration on iPSC-derived CAR cell therapies, terminating a deal originally valued at up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Fate Therapeutics and Janssen Biotech (J&J) announced a worldwide collaboration to develop iPSC-derived CAR NK and CAR T-cell product candidates against up to four tumor-associated antigens. Fate received $50M upfront cash plus $50M equity investment, with eligibility for up to $1.8B in development/regulatory and $1.2B in commercial milestones, plus double-digit royalties. Janssen funded R&D through IND.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Fate Therapeutics, Inc. (this deal) | 2020 | $3.1B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2020 deals · Johnson & Johnson deals · Hematology deals